Lucentis approved in Japan

Article

Lucentis (ranibizumab; Novartis) has been approved for the treatment of wet age-related macular degeneration (AMD) in Japan, Novartis has announced.

Lucentis (ranibizumab; Novartis) has been approved for the treatment of wet age-related macular degeneration (AMD) in Japan, Novartis has announced.

The application for approval in Japan was supported by a clinical trial demonstrating the efficacy of the anti-vascular endothelial growth factor (anti-VEGF) therapy. The approval comes simultaneously with three other Novartis drug approvals in Japan: Tasigna, for cancer, Xolair for asthma and Co-Dio for high blood pressure.

Lucentis has been approved in Europe since February 2007.

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Recent Videos
Andreas Pollreisz, MD, discusses widefield OCT-A and fluorescence angiography at the 2025 European Society of Retina Specialists EURETINA meeting
Harvey Uy, MD, DPBO, FVRSP, speaks about artificial intelligence (AI) and optical coherence tomography (OCT) at the 2025 European Society of Retina Specialists (EURETINA) Congress.
EURETINA 2025: Boris Stanzel, MD, methotrexate is rocking the European retina landscape
© 2025 MJH Life Sciences

All rights reserved.